Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Start-Up News November 2006

Executive Summary

Advances in imaging technologies mean that tiny lung nodules can now be detected, creating a need for technologies for diagnosing and treating lung cancer at early stages. Median Technologies, in computer-assisted detection, PneumRx, with a better biopsy tool, and Perceptronix Medical and Menssana Research, with novel diagnostics, hope to help here.

You may also be interested in...

Lung Cancer: An Up and Coming Device Market

Lung cancer is the number one cause of deaths from cancer, in large part because it generally isn't detected until very late stages. At that point, survival rates are low and the only option is radical lung surgery. But now imaging technologies can detect smaller cancers, sooner, and in the wake of the publication of the Early Lung Cancer Action Project, the medical device industry is preparing for a paradigm shift. Start-ups are now developing technologies to remove the barriers in diagnosis and access that hinder therapeutic intervention.

superDimension Ltd.

superDimension describes its interventional pulmonology device as a"global positioning system" for the lungs. Based on electromagnetic localization technology, superDimension combines a novel, steerable catheter that can maneuver in the tiny vessels at the lungs' periphery, with image-processing and navigation technologies that allow pulmonologists to visualize in real time the path of the catheter as it moves through the lungs.

Finance Watch: Adlai Nortye Raises $97.5m In IPO, Brings US Total To 18

Public Company Edition: Cancer-focused Adlai Nortye launched a concurrent initial public offering and private placement, while four other drug developers announced or completed SPAC mergers. Also, Sobi grossed $540m in a rights issue and Immunovant followed early data with a $450m FOPO.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts